CoChat

MMP-7 is a predictive biomarker of disease progression in patients with idiopathic pulmonary fibrosis

Open access
Bauer, Yasmina, White, Eric S., de Bernard, Simon, Cornelisse, Peter, Leconte, Isabelle, Morganti, Adele, Roux, Sebastien, Nayler, Oliver · 2017 · ERJ Open Research

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Abstract

Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease with poor prognosis, which is characterised by destruction of normal lung architecture and excessive deposition of lung extracellular matrix. The heterogeneity of disease progression in patients with IPF poses significant obstacles to patient care and prevents efficient development of novel therapeutic interventions. Blood biomarkers, reflecting pathobiological processes in the lung, could provide objective evidence of the underlying disease. Longitudinally collected serum samples from the Bosentan Use in Interstitial Lung Disease (BUILD)-3 trial were used to measure four biomarkers (metalloproteinase-7 (MMP-7), Fas death receptor ligand, osteopontin and procollagen type I C-peptide), to assess their potential prognostic capabilities and to follow changes during disease progression in patients with IPF. In baseline BUILD-3 samples, only MMP-7 showed clearly elevated protein levels compared with samples from healthy controls, and further investigations demonstrated that MMP-7 levels also increased over time. Baseline levels of MMP-7 were able to predict patients who had higher risk of worsening and, notably, baseline levels of MMP-7 could predict changes in FVC as early as month 4. MMP-7 shows potential to be a reliable predictor of lung function decline and disease progression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1183/23120541.00074-2016

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIGURE 1 Serum concentrations of procollagen type I C-peptide (PICP), Fas ligand, osteopontin (OPN) and matrix metalloproteinase (MMP)-7 in healthy controls (HCs) and in patients with idiopathic pulmonary fibrosis (IPF) assessed using a multiplex platform. Box plot analysis of serum concentrations of a) PICP, b) FasL, c) OPN and d) MMP-7, in HCs (n=100), and in patients with IPF at baseline (n=113), 4 months (n=102) and end of study (EOS) (n=72). One-sided t-test with unequal variance was used to compare analyte concentrations in HCs and patients with IPF for each analyte at each time point. ns: nonsignificant. **: p≤0.01; #: p≤0.0001.
FIGURE 1 Serum concentrations of procollagen type I C-peptide (PICP), Fas ligand, osteopontin (OPN) and matrix metalloproteinase (MMP)-7 in healthy controls (HCs) and in patients with idiopathic pulmonary fibrosis (IPF) assessed using a multiplex platform. Box plot analysis of serum concentrations of a) PICP, b) FasL, c) OPN and d) MMP-7, in HCs (n=100), and in patients with IPF at baseline (n=113), 4 months (n=102) and end of study (EOS) (n=72). One-sided t-test with unequal variance was used to compare analyte concentrations in HCs and patients with IPF for each analyte at each time point. ns: nonsignificant. **: p≤0.01; #: p≤0.0001.CC BY-NC · PubMed Central
FIGURE 2 Matrix metalloproteinase (MMP)-7 serum protein levels differentiate idiopathic pulmonary fibrosis (IPF) and healthy control (HC) groups 1 and 2 with multiplex and singleplex assays. Serum MMP-7 levels in patients with IPF was increased at baseline in both a) the multiplex assay (IPF, n=342) and in b) the singleplex assay (IPF, n=40) compared with HCs. Note that two different sets of HCs were used: Control-1 (n=100) and Control-2 (n=40). #: p≤0.0001.
FIGURE 2 Matrix metalloproteinase (MMP)-7 serum protein levels differentiate idiopathic pulmonary fibrosis (IPF) and healthy control (HC) groups 1 and 2 with multiplex and singleplex assays. Serum MMP-7 levels in patients with IPF was increased at baseline in both a) the multiplex assay (IPF, n=342) and in b) the singleplex assay (IPF, n=40) compared with HCs. Note that two different sets of HCs were used: Control-1 (n=100) and Control-2 (n=40). #: p≤0.0001.CC BY-NC · PubMed Central
FIGURE 3 Increase in a) matrix metalloproteinase (MMP)-7 serum protein levels in patients with IPF was associated, in the same set of patients, with b) forced vital capacity (FVC) (% predicted value) decrease over time. EOS: end of study. ***: p≤0.001; #: p≤0.0001.
FIGURE 3 Increase in a) matrix metalloproteinase (MMP)-7 serum protein levels in patients with IPF was associated, in the same set of patients, with b) forced vital capacity (FVC) (% predicted value) decrease over time. EOS: end of study. ***: p≤0.001; #: p≤0.0001.CC BY-NC · PubMed Central
FIGURE 4 Scatter plot of the % change versus baseline in pulmonary function test results at a) 4 months and b) the end of the study versus the analyte concentration at baseline. The regression line (grey line) and 95% confidence interval (grey area) are represented. FVC: forced vital capacity; MMP: matrix metalloproteinase.
FIGURE 4 Scatter plot of the % change versus baseline in pulmonary function test results at a) 4 months and b) the end of the study versus the analyte concentration at baseline. The regression line (grey line) and 95% confidence interval (grey area) are represented. FVC: forced vital capacity; MMP: matrix metalloproteinase.CC BY-NC · PubMed Central
FIGURE 5 Kaplan–Meier estimate for clinical worsening in idiopathic pulmonary fibrosis patients a) by matrix metalloproteinase-7 median cut-off level at baseline (B) and b) by the median MMP-7 cut-off level when both baseline and end-of-study (E) values are considered.
FIGURE 5 Kaplan–Meier estimate for clinical worsening in idiopathic pulmonary fibrosis patients a) by matrix metalloproteinase-7 median cut-off level at baseline (B) and b) by the median MMP-7 cut-off level when both baseline and end-of-study (E) values are considered.CC BY-NC · PubMed Central
FIGURE 6 Change in forced vital capacity (FVC) (% predicted) in relation to the evolution of matrix metalloproteinase (MMP)-7 level over time in the same set of patients. a) Baseline <3.8 ng·mL−1 and end-of-study (EOS) MMP-7 >3.8 ng·mL−1, b) baseline and EOS MMP-7 <3.8 ng·mL−1, and c) baseline and EOS MMP-7 ≥3.8 ng·mL−1.
FIGURE 6 Change in forced vital capacity (FVC) (% predicted) in relation to the evolution of matrix metalloproteinase (MMP)-7 level over time in the same set of patients. a) Baseline <3.8 ng·mL−1 and end-of-study (EOS) MMP-7 >3.8 ng·mL−1, b) baseline and EOS MMP-7 <3.8 ng·mL−1, and c) baseline and EOS MMP-7 ≥3.8 ng·mL−1.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 36 references

Cited by

See all 140

Metadata

Authors
Bauer, Y., White, E. S., de Bernard, S., Cornelisse, P., Leconte, I., Morganti, A., Roux, S., & Nayler, O.
Affiliations
  • Actelion (Switzerland) (CH)
  • University of Michigan (US)
Corresponding author
Bauer, Yasmina
Venue
ERJ Open Research
Published
2017-01
Volume
3
Issue
1
Pages
00074-2016
ISSN
2312-0541 (ISSN-L)
OpenAlex
W2603140425
Cited by
139
References
36
Citations by year
2026: 16 · 2025: 19 · 2024: 23 · 2023: 14 · 2022: 7 · 2021: 17 · 2020: 13 · 2019: 16 · 2018: 13 · 2017: 1
FWCI
9.73
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • ERJ Open Research (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • NIH Office of the Director (R01 HL109118)
  • Drews Sarcoidosis research fund
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
Keywords
idiopathic pulmonary fibrosis, MMP-7, predictive biomarkers, disease progression, osteopontin, lung function decline, forced vital capacity, serum biomarkers, interstitial lung disease, bosentan

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: MMP-7 is a predictive biomarker of disease progression in patients with idiopathic pulmonary fibrosis. https://app.cochat.ai/papers/10.1183/23120541.00074-2016
The paper
Bauer, Y., White, E. S., de Bernard, S., Cornelisse, P., Leconte, I., Morganti, A., Roux, S., & Nayler, O. (2017). MMP-7 is a predictive biomarker of disease progression in patients with idiopathic pulmonary fibrosis. ERJ Open Research. https://doi.org/10.1183/23120541.00074-2016

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.